Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
5
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Restaysis
For the treatment of moderate dry eye disease in adults.
Vevizye
Treatment of moderate to severe dry eye disease (keratoconjunctivitis sicca) in adult patients, which has not improved despite treatment with tear substitutes.
View on EMAVerkazia
Treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents.
Ikervis
Treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes.
View on EMA